In this issue:
Comparing survival with front-line regimens in elderly AML
Gemtuzumab ozogamicin in NPM1-mutated AML
NGS-detectable mutations in CML with nonoptimal response
Dasatinib discontinuation in chronicphase CML with stable deep MR
Ivosidenib induces durable remissions in newly diagnosed IDH1-mutated AML
Infections among ibrutinib recipients with B-cell malignancies
CAR-transduced NK cells in CD19-positive lymphoid tumours
Outcomes of limited-stage, high-risk aggressive large B-cell lymphoma
Bendamustine + rituximab in elderly DLBCL
Please login below to download this issue (PDF)